Research Advancements and Perspectives of Inflammatory Bowel Disease: A Comprehensive Review

Overview

Journal Sci Prog

Publisher Sage Publications

Specialty Science

Date 2024 May 23

PMID 38778725

Authors

Junyi Bai

Ying Wang

Fuhao Li

Yueyao Wu

Jun Chen

Meng Li

Xi Wang

Bin Lv

Affiliations

Soon will be listed here.

Abstract

Inflammatory bowel disease (IBD) is a chronic inflammatory disease with increasing incidence, such as Crohn's disease and ulcerative colitis. The accurate etiology and pathogenesis of IBD remain unclear, and it is generally believed that it is related to genetic susceptibility, gut microbiota, environmental factors, immunological abnormalities, and potentially other factors. Currently, the mainstream therapeutic drugs are amino salicylic acid agents, corticosteroids, immunomodulators, and biological agents, but the remission rates do not surpass 30-60% of patients in a real-life setting. As a consequence, there are many studies focusing on emerging drugs and bioactive ingredients that have higher efficacy and long-term safety for achieving complete deep healing. This article begins with a review of the latest, systematic, and credible summaries of the pathogenesis of IBD. In addition, we provide a summary of the current treatments and drugs for IBD. Finally, we focus on the therapeutic effects of emerging drugs such as microRNAs and lncRNAs, nanoparticles-mediated drugs and natural products on IBD and their mechanisms of action.

Citing Articles

The Biology and Clinical Implications of PCSK7.

Sachan V, Susan-Resiga D, Lam K, Seidah N Endocr Rev. 2024; 46(2):281-299.

PMID: 39661471 PMC: 11894536. DOI: 10.1210/endrev/bnae031.

Harnessing a Safe Novel Lipid Nanoparticle: Targeted Oral Delivery to Colonic Epithelial and Macrophage Cells in a Colitis Mouse Model.

Mow R, Kuczma M, Shi X, Mani S, Merlin D, Yang C Nanomaterials (Basel). 2024; 14(22).

PMID: 39591041 PMC: 11597058. DOI: 10.3390/nano14221800.

Macrophages and Gut Barrier Function: Guardians of Gastrointestinal Health in Post-Inflammatory and Post-Infection Responses.

Meng E, Verne G, Zhou Q Int J Mol Sci. 2024; 25(17).

PMID: 39273369 PMC: 11395020. DOI: 10.3390/ijms25179422.

References

Sommer K, Heidbreder K, Kreiss L, Dedden M, Paap E, Wiendl M . Anti-β7 integrin treatment impedes the recruitment on non-classical monocytes to the gut and delays macrophage-mediated intestinal wound healing. Clin Transl Med. 2023; 13(4):e1233. PMC: 10082567. DOI: 10.1002/ctm2.1233. View

Liu T, Ning Z, Liu P, Gao H . Cassane diterpenoid ameliorates dextran sulfate sodium-induced experimental colitis by regulating gut microbiota and suppressing tryptophan metabolism. Front Immunol. 2023; 13:1045901. PMC: 9893013. DOI: 10.3389/fimmu.2022.1045901. View

Hong D, Kang Y, Borad M, Sachdev J, Ejadi S, Lim H . Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. Br J Cancer. 2020; 122(11):1630-1637. PMC: 7251107. DOI: 10.1038/s41416-020-0802-1. View

Yu T, Kalakonda S, Liu X, Han N, Chung H, Xiao L . Long noncoding RNA uc.230/CUG-binding protein 1 axis sustains intestinal epithelial homeostasis and response to tissue injury. JCI Insight. 2022; 7(19). PMC: 9675575. DOI: 10.1172/jci.insight.156612. View

Lee Y, Shin D, Lim B . Chlorogenic Acid Improves Symptoms of Inflammatory Bowel Disease in Interleukin-10 Knockout Mice. J Med Food. 2020; 23(10):1043-1053. DOI: 10.1089/jmf.2019.4621. View

Zhao C, Yang J, Chen M, Chen W, Yang X, Ye H . Synthetic Lignin-Derived Therapeutic Nano Reagent as Intestinal pH-Sensitive Drug Carriers Capable of Bypassing the Gastric Acid Environment for Colitis Treatment. ACS Nano. 2022; 17(1):811-824. DOI: 10.1021/acsnano.2c11188. View

Alharbi T, Alshammari Z, Alanzi Z, Althobaiti F, Elewa M, Hashem K . Therapeutic effects of genistein in experimentally induced ulcerative colitis in rats via affecting mitochondrial biogenesis. Mol Cell Biochem. 2023; 479(2):431-444. DOI: 10.1007/s11010-023-04746-8. View

Chang Y, Kim J, Yang S, Chung D, Ko J, Moon J . Increased GM-CSF-producing NCR ILC3s and neutrophils in the intestinal mucosa exacerbate inflammatory bowel disease. Clin Transl Immunology. 2021; 10(7):e1311. PMC: 8264747. DOI: 10.1002/cti2.1311. View

Huang J, Xu P, Shao M, Wei B, Zhang C, Zhang J . Humic acids alleviate dextran sulfate sodium-induced colitis by positively modulating gut microbiota. Front Microbiol. 2023; 14:1147110. PMC: 10132312. DOI: 10.3389/fmicb.2023.1147110. View

10.

Chen J, Lu P, Liu J, Yang L, Li Y, Chen Y . 20(S)- Protopanaxadiol saponins isolated from Panax notoginseng target the binding of HMGB1 to TLR4 against inflammation in experimental ulcerative colitis. Phytother Res. 2023; 37(10):4690-4705. DOI: 10.1002/ptr.7938. View

11.

Fujikawa H, Shimizu H, Nambu R, Takeuchi I, Matsui T, Sakamoto K . Monogenic inflammatory bowel disease with STXBP2 mutations is not resolved by hematopoietic stem cell transplantation but can be alleviated via immunosuppressive drug therapy. Clin Immunol. 2022; 246:109203. DOI: 10.1016/j.clim.2022.109203. View

12.

Bos A, van Gool M, Breedveld A, van der Mast R, Marsman C, Bouma G . Fcα Receptor-1-Activated Monocytes Promote B Lymphocyte Migration and IgA Isotype Switching. Int J Mol Sci. 2022; 23(19). PMC: 9569671. DOI: 10.3390/ijms231911132. View

13.

Gurtner A, Borrelli C, Gonzalez-Perez I, Bach K, Acar I, Nunez N . Active eosinophils regulate host defence and immune responses in colitis. Nature. 2022; 615(7950):151-157. PMC: 9977678. DOI: 10.1038/s41586-022-05628-7. View

14.

Ma H, Hu T, Tao W, Tong J, Han Z, Herndler-Brandstetter D . A lncRNA from an inflammatory bowel disease risk locus maintains intestinal host-commensal homeostasis. Cell Res. 2023; 33(5):372-388. PMC: 10156687. DOI: 10.1038/s41422-023-00790-7. View

15.

Masuta Y, Minaga K, Kurimoto M, Sekai I, Hara A, Omaru N . Activation of nucleotide-binding oligomerization domain 2 by muramyl dipeptide negatively regulates Toll-like receptor 9-mediated colonic inflammation through the induction of deubiquitinating enzyme A expression. Int Immunol. 2022; 35(2):79-94. DOI: 10.1093/intimm/dxac045. View

16.

Vich Vila A, Hu S, Andreu-Sanchez S, Collij V, Jansen B, Augustijn H . Faecal metabolome and its determinants in inflammatory bowel disease. Gut. 2023; 72(8):1472-1485. PMC: 10359577. DOI: 10.1136/gutjnl-2022-328048. View

17.

Dong D, Su T, Chen W, Wang D, Xue Y, Lu Q . aggravates dextran sulfate solution (DSS)-induced colitis by shaping the gut microbiota and promoting neutrophil recruitment. Gut Microbes. 2023; 15(1):2192478. PMC: 10038061. DOI: 10.1080/19490976.2023.2192478. View

18.

Kittana H, Gomes-Neto J, Heck K, Juritsch A, Sughroue J, Xian Y . Evidence for a Causal Role for Escherichia coli Strains Identified as Adherent-Invasive (AIEC) in Intestinal Inflammation. mSphere. 2023; 8(2):e0047822. PMC: 10117065. DOI: 10.1128/msphere.00478-22. View

19.

Olli K, Rapp C, OConnell L, Collins C, McNamee E, Jensen O . Muc5ac Expression Protects the Colonic Barrier in Experimental Colitis. Inflamm Bowel Dis. 2020; 26(9):1353-1367. PMC: 7441107. DOI: 10.1093/ibd/izaa064. View

20.

Oliveira E, Dalmau L, de Almeida Costa C, de Almeida Junior L, Ballard C, Marostica Junior M . Dietary intervention with avocado (Persea americana Mill.) ameliorates intestinal inflammation induced by TNBS in rats. Inflammopharmacology. 2022; 31(1):485-498. DOI: 10.1007/s10787-022-01128-2. View